101 related articles for article (PubMed ID: 10591487)
1. NAD(P)H: quinone oxidoreductase polymorphism and lung cancer in Taiwan.
Lin P; Wang HJ; Lee H; Lee HS; Wang SL; Hsueh YM; Tsai KJ; Chen CY
J Toxicol Environ Health A; 1999 Oct; 58(4):187-97. PubMed ID: 10591487
[TBL] [Abstract][Full Text] [Related]
2. Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan.
Lin P; Hsueh YM; Ko JL; Liang YF; Tsai KJ; Chen CY
Lung Cancer; 2003 May; 40(2):123-9. PubMed ID: 12711112
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China.
Yin L; Pu Y; Liu TY; Tung YH; Chen KW; Lin P
Lung Cancer; 2001; 33(2-3):133-41. PubMed ID: 11551408
[TBL] [Abstract][Full Text] [Related]
4. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism.
Wiencke JK; Spitz MR; McMillan A; Kelsey KT
Cancer Epidemiol Biomarkers Prev; 1997 Feb; 6(2):87-92. PubMed ID: 9037558
[TBL] [Abstract][Full Text] [Related]
5. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
Takakuwa O; Oguri T; Ozasa H; Uemura T; Kunii E; Kasai D; Miyazaki M; Maeno K; Sato S
J Thorac Oncol; 2011 Nov; 6(11):1826-32. PubMed ID: 21964527
[TBL] [Abstract][Full Text] [Related]
6. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis.
Chao C; Zhang ZF; Berthiller J; Boffetta P; Hashibe M
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):979-87. PubMed ID: 16702380
[TBL] [Abstract][Full Text] [Related]
7. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese.
Hamajima N; Matsuo K; Iwata H; Shinoda M; Yamamura Y; Kato T; Hatooka S; Mitsudomi T; Suyama M; Kagami Y; Ogura M; Ando M; Sugimura Y; Tajima K
Int J Clin Oncol; 2002 Apr; 7(2):103-8. PubMed ID: 12018106
[TBL] [Abstract][Full Text] [Related]
8. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking.
Rosvold EA; McGlynn KA; Lustbader ED; Buetow KH
Pharmacogenetics; 1995 Aug; 5(4):199-206. PubMed ID: 8528266
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population.
Alexandrie AK; Nyberg F; Warholm M; Rannug A
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):908-14. PubMed ID: 15184245
[TBL] [Abstract][Full Text] [Related]
10. NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer.
Harth V; Donat S; Ko Y; Abel J; Vetter H; Brüning T
Arch Toxicol; 2000 Jan; 73(10-11):528-31. PubMed ID: 10663383
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population.
Lewis SJ; Cherry NM; Niven RM; Barber PV; Povey AC
Lung Cancer; 2001 Nov; 34(2):177-83. PubMed ID: 11679176
[TBL] [Abstract][Full Text] [Related]
12. Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan.
Wang YH; Lee YH; Tseng PT; Shen CH; Chiou HY
J Cancer Res Clin Oncol; 2008 Feb; 134(2):203-9. PubMed ID: 17619904
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of the NQO1 C609T Polymorphism in Non Small Cell Lung Adenocarcinoma Patients.
Masroor M; Jain A; Javid J; Mir R; Prashant Y; Imtiyaz A; Mariyam Z; Mohan A; Ray PC; Saxena A
Asian Pac J Cancer Prev; 2015; 16(17):7653-8. PubMed ID: 26625776
[TBL] [Abstract][Full Text] [Related]
14. Role of NQO1 609C>T and NQO2-3423G>A polymorphisms in susceptibility to gastric cancer in Kashmir valley.
Malik MA; Zargar SA; Mittal B
DNA Cell Biol; 2011 May; 30(5):297-303. PubMed ID: 21294640
[TBL] [Abstract][Full Text] [Related]
15. An association between a NQO1 genetic polymorphism and risk of lung cancer.
Saldivar SJ; Wang Y; Zhao H; Shao L; Lin J; Spitz MR; Wu X
Mutat Res; 2005 Apr; 582(1-2):71-8. PubMed ID: 15781212
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase).
Traver RD; Siegel D; Beall HD; Phillips RM; Gibson NW; Franklin WA; Ross D
Br J Cancer; 1997; 75(1):69-75. PubMed ID: 9000600
[TBL] [Abstract][Full Text] [Related]
17. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis.
Lou Y; Li R; Xiong L; Gu A; Shi C; Chu T; Zhang X; Gu P; Zhong H; Wen S; Han B
Tumour Biol; 2013 Dec; 34(6):3967-79. PubMed ID: 23852860
[TBL] [Abstract][Full Text] [Related]
18. Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract.
Sarbia M; Bitzer M; Siegel D; Ross D; Schulz WA; Zotz RB; Kiel S; Geddert H; Kandemir Y; Walter A; Willers R; Gabbert HE
Int J Cancer; 2003 Nov; 107(3):381-6. PubMed ID: 14506737
[TBL] [Abstract][Full Text] [Related]
19. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population.
Sameer AS; Shah ZA; Syeed N; Rasool R; Afroze D; Siddiqi MA
Asian Pac J Cancer Prev; 2010; 11(1):209-13. PubMed ID: 20593958
[TBL] [Abstract][Full Text] [Related]
20. A NAD(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer.
Begleiter A; Hewitt D; Maksymiuk AW; Ross DA; Bird RP
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2422-6. PubMed ID: 17164365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
